These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33459258)

  • 41. Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial.
    Gastaminza G; Azofra J; Nunez-Cordoba JM; Baeza ML; Echechipía S; Gaig P; García BE; Labrador-Horrillo M; Sala-Cunill A; Brescó MS; Beristain A; Quiñones D; Donado CD; Zubeldia JM; Ferrer M
    J Allergy Clin Immunol Pract; 2019; 7(5):1599-1609.e1. PubMed ID: 30654196
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Model-based meta-analysis of omalizumab in treating patients with chronic idiopathic/spontaneous urticaria.
    Zhao A; Zhang K; Wang Z; Ye K; Xu Z; Gong X; Zhu G
    J Evid Based Med; 2024 Jun; 17(2):242-244. PubMed ID: 38572834
    [No Abstract]   [Full Text] [Related]  

  • 43. COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab.
    Baldallo C; León Román JC; Serón D; Agraz I; Solans R; Ramos N; Soler MJ
    Nefrologia (Engl Ed); 2021; 41(3):354-356. PubMed ID: 32826086
    [No Abstract]   [Full Text] [Related]  

  • 44. Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria.
    Baumann K; Jørgensen AR; Sørensen JA; Zhang DG; Ghazanfar MN; Skov PS; Woetmann A; Vestergaard C; Maurer M; Thomsen SF
    Clin Exp Allergy; 2023 Dec; 53(12):1318-1321. PubMed ID: 37771063
    [No Abstract]   [Full Text] [Related]  

  • 45. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems.
    Sánchez J; Alvarez L; López JF
    Actas Dermosifiliogr; 2024 Jan; 115(1):T88-T90. PubMed ID: 37871896
    [No Abstract]   [Full Text] [Related]  

  • 46. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems.
    Sánchez J; Alvarez L; López JF
    Actas Dermosifiliogr; 2024 Jan; 115(1):88-90. PubMed ID: 36754254
    [No Abstract]   [Full Text] [Related]  

  • 47. Baseline D-dimer plasma levels correlate with disease activity but not with the response to omalizumab in chronic spontaneous urticaria.
    Asero R; Marzano AV; Ferrucci S; Genovese G; Cugno M
    Allergy; 2019 Dec; 74(12):2538. PubMed ID: 31165493
    [No Abstract]   [Full Text] [Related]  

  • 48. Age and fast initial response predict omalizumab retreatment in chronic urticaria.
    Meertens MAJ; Luijf T; van Lindonk EAM; Soegiharto R; Assil S; Alizadeh Aghdam M; Kentie PA; Knulst AC; van Doorn MBA; Röckmann H
    J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3556-3558.e1. PubMed ID: 37517795
    [No Abstract]   [Full Text] [Related]  

  • 49. Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety.
    Ocak M; Soyer O; Buyuktiryaki B; Sekerel BE; Sahiner UM
    Allergol Immunopathol (Madr); 2020; 48(4):368-373. PubMed ID: 32467066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recalcitrant chronic urticaria treated with dupilumab: Report of two instances refractory to H1-antihistamines, omalizumab and cyclosporine and brief literature review.
    Errichetti E; Stinco G
    Dermatol Ther; 2021 Mar; 34(2):e14821. PubMed ID: 33506984
    [No Abstract]   [Full Text] [Related]  

  • 51. Omalizumab re-treatment rates in chronic spontaneous urticaria.
    Khan S; Sholtysek S
    Eur Ann Allergy Clin Immunol; 2020 May; 52(4):187-189. PubMed ID: 32378397
    [No Abstract]   [Full Text] [Related]  

  • 52. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
    Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful treatment of urticarial vasculitis with omalizumab in children: a case series.
    Wang S; Fu L; Xiang X; Zhang B; Ma L; Xing H
    Clin Exp Dermatol; 2023 Sep; 48(10):1145-1148. PubMed ID: 37227921
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of omalizumab treatment on peripheral nerves in patients with chronic spontaneous urticaria.
    Altunisik E; Inan Dogan E
    Cutan Ocul Toxicol; 2021 Jun; 40(2):130-134. PubMed ID: 33902373
    [No Abstract]   [Full Text] [Related]  

  • 55. How does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria?
    Önder S; Ozturk M
    Cutan Ocul Toxicol; 2020 Mar; 39(1):31-35. PubMed ID: 31642341
    [No Abstract]   [Full Text] [Related]  

  • 56. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
    Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
    Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors related to omalizumab resistance in chronic spontaneous urticaria.
    Magen E; Chikovani T; Waitman DA; Kahan NR
    Allergy Asthma Proc; 2019 Jul; 40(4):273-278. PubMed ID: 31262381
    [No Abstract]   [Full Text] [Related]  

  • 58. Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study.
    Abduelmula A; Georgakopoulos JR; Mufti A; Devani AR; Gooderham MJ; Hong CH; Jain V; Lansang P; Vender R; Prajapati VH; Yeung J
    J Cutan Med Surg; 2022; 26(3):319-320. PubMed ID: 34587789
    [No Abstract]   [Full Text] [Related]  

  • 59. Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: A long-term observational study.
    Di Bona D; Nettis E; Bilancia M; Ridolo E; Minenna E; Nizi MC; Albanesi M; Caiaffa MF; Macchia L
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2482-2485.e2. PubMed ID: 33677081
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.